The US Food and Drug Administration should more clearly explain how it uses patient experience data in its approval decisions for drugs and biologics, an independent consultant has recommended.
Applicants, patients, caregivers and other stakeholders cannot easily determine how the FDA uses patient experience data (PED) in regulatory decision-making,...








